ES2546866T3 - Polimorfos de darunavir - Google Patents

Polimorfos de darunavir Download PDF

Info

Publication number
ES2546866T3
ES2546866T3 ES09852224.6T ES09852224T ES2546866T3 ES 2546866 T3 ES2546866 T3 ES 2546866T3 ES 09852224 T ES09852224 T ES 09852224T ES 2546866 T3 ES2546866 T3 ES 2546866T3
Authority
ES
Spain
Prior art keywords
darunavir
polymorphs
solvate
alcohol
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09852224.6T
Other languages
English (en)
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Rapolu Raji Reddy
Kesireddy Subash Chander Reddy
Bandi Vamsi Krishan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Application granted granted Critical
Publication of ES2546866T3 publication Critical patent/ES2546866T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Un solvato de alcohol C5 de darunavir.

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES09852224.6T 2009-12-16 2009-12-16 Polimorfos de darunavir Active ES2546866T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2009/000724 WO2011073993A1 (en) 2009-12-16 2009-12-16 Polymorphs of darunavir

Publications (1)

Publication Number Publication Date
ES2546866T3 true ES2546866T3 (es) 2015-09-29

Family

ID=44166823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09852224.6T Active ES2546866T3 (es) 2009-12-16 2009-12-16 Polimorfos de darunavir

Country Status (7)

Country Link
US (3) US20110313035A1 (es)
EP (1) EP2513116B1 (es)
CN (1) CN102686594A (es)
CA (1) CA2784131C (es)
ES (1) ES2546866T3 (es)
PT (1) PT2513116E (es)
WO (1) WO2011073993A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
CN102686594A (zh) 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物
JP2013516397A (ja) * 2010-01-05 2013-05-13 シプラ・リミテッド ダルナビルの多形及びその製造方法
ES2516916T3 (es) 2010-01-28 2014-10-31 Mapi Pharma Limited Procedimiento para la preparación de darunavir e intermedios de darunavir
EP2571355B1 (en) 2010-05-20 2016-09-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
EP2804869B1 (en) 2012-01-18 2019-06-12 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
EP3795572B1 (en) 2012-07-24 2023-11-15 Laurus Labs Limited Darunavir propionate solvate
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
CN106854212A (zh) * 2015-12-08 2017-06-16 浙江九洲药业股份有限公司 一种达芦那韦无定型的制备方法
CN107235987A (zh) * 2016-03-28 2017-10-10 浙江九洲药业股份有限公司 一种地瑞那韦甲醇溶剂化物及其制备方法和用途
ES2881949T3 (es) 2016-10-27 2021-11-30 Gilead Sciences Inc Forma cristalina de base libre de darunavir
CN108794498A (zh) * 2017-05-03 2018-11-13 江苏瑞科医药科技有限公司 一种达芦那韦无定型的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7310889A (es) 1972-08-12 1974-02-14
US4670578A (en) * 1983-08-29 1987-06-02 Merck & Co., Inc. Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5315016A (en) * 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
DE69415326T2 (de) 1993-08-24 1999-06-02 G.D. Searle & Co., Chicago, Ill. Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
WO1999067417A2 (en) 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods
US20030125336A1 (en) 2001-05-30 2003-07-03 Fleitz Fred J. Hydrohalide salts of an HIV protease inhibitor
DK2767539T3 (en) * 2002-05-16 2017-09-11 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
EP2463268B1 (en) * 2004-12-02 2013-08-28 Daiichi Sankyo Company, Limited 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
EP1963254A2 (en) * 2005-09-21 2008-09-03 Torrent Pharmaceuticals Ltd Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
AR057182A1 (es) 2005-11-28 2007-11-21 Tibotec Pharm Ltd Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
SI2089371T1 (sl) 2006-11-09 2011-05-31 Tibotec Pharm Ltd Postopki za pripravo heksahidrofuro(2,3-b)furan-3-ola
CA2750774A1 (en) 2009-01-29 2010-08-05 Mapi Pharma Hk Limited Polymorphs of darunavir
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
PL2417107T3 (pl) * 2009-04-09 2016-02-29 Sandoz Ag Krystaliczne postacie saksagliptyny
CN102686594A (zh) 2009-12-16 2012-09-19 熙德隆研究基金会 地瑞那韦的多晶型物
EP2571355B1 (en) 2010-05-20 2016-09-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir

Also Published As

Publication number Publication date
EP2513116B1 (en) 2015-08-19
US20110313035A1 (en) 2011-12-22
PT2513116E (pt) 2015-10-14
CN102686594A (zh) 2012-09-19
US9624236B2 (en) 2017-04-18
WO2011073993A1 (en) 2011-06-23
US20120288563A1 (en) 2012-11-15
EP2513116A4 (en) 2013-05-08
CA2784131C (en) 2017-07-11
US9580440B2 (en) 2017-02-28
CA2784131A1 (en) 2011-06-23
US20140200356A1 (en) 2014-07-17
EP2513116A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
ES2546866T3 (es) Polimorfos de darunavir
ES2497167T5 (es) Una composición de bebida
ES2548578T3 (es) Monosebacato de un derivado de pirazol
ES2500067T3 (es) Compuesto bicíclico y uso del mismo para fines médicos
ES2644809T3 (es) Sistema de generación de gas inerte a bordo
ES2448766T9 (es) Profármacos de dolutegravir
ES2642212T3 (es) Cierre de cremallera
ES2403197T5 (es) Instalación de lavado
BRPI0914239A2 (pt) método para produção de uma estrutura de parede anular
CR20120295A (es) Triazolopiridinas
BRPI0923797A2 (pt) Método para produzir um éster.
ES2642399T3 (es) Material cosmético emulsionado
ES2644443T3 (es) Producción biotecnológica de condroitina
ES2642325T3 (es) Sonda de temperatura de núcleo
BR112012005592A2 (pt) geração de sementes oleaginosas produzindo alto poliidroxibutirato.
UY34442A (es) 2-tiopirimidinonas.
ES2567082T9 (es) Transformador de turbina eólica
EA201070538A1 (ru) Улучшенный способ получения сложных диэфиров
ES2485373T3 (es) Compuestos que actúan en múltiples receptores de prostaglandina proporcionando una respuesta anti-inflamatoria general
DE602007013981D1 (de) Bilderzeugungsvorrichtung
ES2642085T3 (es) Procedimientos anaeróbicos de tratamiento de lodos
DE602007012174D1 (de) Bilderzeugungsvorrichtung
ES2578160T3 (es) Procedimiento de diagnóstico de infecciones de sitio quirúrgico
DE602008004602D1 (de) Bilderzeugungsvorrichtung
EP3948237A4 (en) ENHANCED SAMPLE IMAGING USING STRUCTURED ILLUMINATION MICROSCOPY